News - Stelara Injection, Biotechnology

Filter

Popular Filters

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Johnson & Johnson's Stelara gains FDA approval for psoriatic arthritis

24-09-2013

Janssen Research & Development announced that the US Food and Drug Administration has approved Stelara…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechNorth AmericaRegulationStelara Injection

Janssen files Stelara for active psoriatic arthritis in USA and EU

07-12-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen yesterday submitted a supplemental…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationStelara Injection

Study finds potential use of ustekinumab for Crohn's disease

18-10-2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Back to top